For Immediate Release
Alembic Pharmaceuticals Limited Consolidated Results for Quarter/Year ended 31.03.2015 Editor’s Synopsis A) Quarter ended 31st March 2015 •
Successfully passed US FDA audit of formulation facility at Panelav without any 483 observations
•
Successfully passed US FDA audit of Bio equivalence center without any 483 observations
•
Net sales up by 9% to Rs 508.0 crores against Rs 465.2 crores
•
Profit before tax up by 10% to Rs 88.5 crores against Rs 80.8 crores
•
Net profit after tax up by 15% to Rs 70.3 crores against Rs 61.3 crores
B) Year ended 31st March 2015 •
Net sales up by 11% to Rs 2067.7 crores against Rs 1868.4 crores
•
Profit before tax up by 16% to Rs 359.1 crores against Rs 310.6 crores
•
Net profit after tax up by 20% to Rs 282.9 crores against Rs 235.5 crores
•
EBITDA margins at 19.6% at Rs 406.1 crores compared to 19.1% at Rs 357.7 crores
C) Appointment of Mr. Pranav Amin and Mr. Shaunak Amin as Joint Managing Directors of the Company Vadodara, 27th April, 2015 Page: 1 of 4
Alembic Pharmaceuticals Limited reported a 9% increase in revenues to Rs 508.0 crores for the quarter ended 31st March 2015, compared to Rs 465.2 crores in the corresponding quarter last year. The Company posted 10% growth in profit before tax at Rs 88.5 crores for the quarter ended 31st March 2015 against Rs 80.8 crores posted in the corresponding quarter last year. The net profit grew by 15% at Rs 70.3 crores for the quarter ended 31st March 2015 against Rs 61.3 crores in the corresponding quarter last year. The company reported 11% increase in revenue for year ended 31st March 2015 to Rs 2067.7 crores against Rs 1868.4 crores in the last year. The Company reported 16% growth in profit before tax at Rs. 359.1 crores for Year ended 31st March 2015 against Rs. 310.6 crores in the last year. The company also reported 20% growth in net profit for year ended 31st March 2015 Rs 282.9 crores against Rs 235.5 crores in the last year. Mr. Pranav Amin and Mr. Shaunak Amin were earlier designated as Director & President – International Business and Director & President – Branded Formulations Business respectively. The Company has made significant growth under their leadership and considering their roles and responsibilities, are being redesignated as Joint Managing Directors of the Company with effect from 27th April 2015.
Dividend The Board has recommended dividend on equity shares at Rs 3.50 per share i.e. 175% for 14-15 (P.Y. Rs 3.00 per share i.e. 150%) India Branded Formulations Business The India Branded formulations business grew by 16% to Rs 232.1 crores in the quarter against Rs 199.4 crores over the corresponding quarter of the previous year. The India Branded formulations business posted sales for year ended 31st March 2015 of Rs 980.8 crores against Rs 850.6 crores with 15% growth over the previous year. Page: 2 of 4
Specialty and Acute segments grew by 22% and 11% respectively in current quarter. For the year the growth are 21% and 9% respectively for Specialty and Acute segments. International Generics International Generic Formulation grew by 8% to Rs 147.9 crores in the quarter against Rs 136.6 crores over the corresponding quarter of the previous year. International Generic Formulation posted sales for the year ended 31st March 2015 of Rs 518.5 crores against Rs 468.4 crores with 11% growth over the previous year. 2 ANDA applications were filed during the quarter, 7 ANDA applications for the year ended 31st March 2015, taking cumulative ANDA/NDA filings of the Company to 68. During the quarter 1 ANDA approval was received, 5 ANDA approvals for the year ended 31st March 2015, taking cumulative ANDA/NDA approvals to 37 (including 4 tentative approvals). 2 DMF applications were filed during the quarter, 6 DMF applications for the year ended 31st March 2015, taking cumulative DMF filings of the Company to 72. Summary of Total Revenue is as under: (Rs in Lacs) Particulars Formulation India Branded India Generics International Branded International Generics API Export Incentives Total
Q4 FY15
Q4 FY14
% Change
FY 14-15
FY 13-14
% Change
23208 3209 903 14788
19945 2867 1759 13665
16% 12% (-)49% 8%
98084 12274 6349 51845
85064 12071 7360 46837
15% 2% (-)14% 11%
8524
8098
5%
36650
33885
8%
163
188
-
1571
1624
-
50795
46522
9%
206773
186841
11%
Page: 3 of 4
The Profit break-up is as under: (Rs in Lacs) Q4 FY15
Q4 FY14
% Change
FY 14-15
FY 13-14
% Change
EBITDA
9866
9129
8%
40607
35771
14%
Profit Before Tax
8848
8078
10%
35908
31060
16%
Net Profit after Tax
7033
6129
15%
28293
23550
20%
Particulars
About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients. Information about the company can be found at www.alembicindia.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573) For more information contact: Alembic Pharmaceuticals Limited Ajay Kumar Desai Phone: +91 22 – 306 11681 Email:
[email protected] Mitanshu Shah Phone: +91 265 – 3007630 Email:
[email protected]
Page: 4 of 4
